Organogenesis Holdings Inc.
Every calculator, already run for ORGO
Open the full toolkit →You have the numbers on ORGO. Get the argument.
A written report on which of these readings actually decide the outcome for Organogenesis Holdings Inc., what has to stay true for the price to work, and the specific thing that would break it. The first one is free.
Key market data
Analyst consensus
2 analysts covering ORGOOwnership & short interest
Insider Trading Activity for ORGO
| Insider | Role | Type | Shares | Price | Value | Date | Filing |
|---|---|---|---|---|---|---|---|
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barr…
ORGO — frequently asked
Is ORGO a buy right now?
Wall Street's consensus rating on Organogenesis Holdings Inc. is none across 2 analysts, with a mean price target of $2.00 (+41% vs. the current $1.42). Ratings are a starting point — run the DCF and check the financial-health readings above before deciding.
Is ORGO overvalued?
ORGO trades at — trailing earnings, against a DCF fair value of $5 per share. The current price implies -10% annual free-cash-flow growth for a decade. Open the DCF or reverse-DCF tool to change the assumptions and see the range.
When is ORGO's next earnings date?
Organogenesis Holdings Inc. is next scheduled to report earnings around Nov 5, 2026. A full ORGO research report from Basis Report covers the setup into that print — estimates, the beat/miss record, and what would move the thesis.
Compare Organogenesis Holdings Inc. against related stocks
Explore additional stock overview pages and jump directly into full report generation for each symbol.
Sector peers
Most-followed names in the same sector.
Nearby tickers
Additional public equities from our tracked universe.
Market leaders
Large-cap symbols investors frequently compare.
Investor Guides For Organogenesis Holdings Inc.
Start with the evergreen guides that matter most for Healthcare, then move back into the ticker page when you want to pressure-test the framework on a live name.
Generate your full ORGO research report
DCF model, five-year financials, moat assessment, a BUY/HOLD/SELL rating, and the risks that matter — on Organogenesis Holdings Inc., in minutes. 3 free reports included with every account — no credit card required.